In 2026 semaglutide titration delivers about 5.5% loss while tirzepatide pushes results to 15%. Find out which protocol suits rare MC4R deficiency and why the dosing schedule matters.
For further actions, you may consider blocking this person and/or reporting abuse
Top comments (0)